Back to results
US 11,833,228 B2Granted
Fluorinated beta-hydroxybutyric acids for PET imaging
AssigneeThe Governors of the University of Alberta
InventorsStephanie Mattingly, Frank Wuest, Ralf Schirrmacher, Melinda Wuest, Eugene Fine
Life of this patent
Estimating the term…
Abstract
Beta-hydroxybutyric acid-based radiopharmaceuticals, pharmaceutical compositions comprising same, methods for preparing same, and methods of using same for diagnostic imaging and non-imaging tracer studies are provided.
Claims13
A compound of:
- (a) (S)-[18F]γ-fluoro-β-hydroxybutyric acid having the absolute stereochemistry of formula (I):
- wherein the hydroxylated carbon at position 3 has (S) stereochemistry;
- or a pharmaceutically acceptable salt, solvate, or hydrate thereof;
- or
- (b) (R)-[18F]γ-fluoro-β-hydroxybutyric acid having the absolute stereochemistry of formula (II):
- wherein the hydroxylated carbon at position 3 has (R) stereochemistry;
- or a pharmaceutically acceptable salt, solvate, or hydrate thereof.
4 more elements
A method for diagnosing, staging, or treating a disorder in a subject comprising:
- administering a radiopharmaceutical to the subject;
- and
- imaging an organ or tissue of interest using positron emission tomography;
- wherein the radiopharmaceutical comprises the compound of (S)-[18F]γ-fluoro-β-hydroxybutyric acid having the absolute stereochemistry of formula (I)
- wherein the hydroxylated carbon at position 3 has (S) stereochemistry, (R)-[18 F]γ-fluoro-β-hydroxybutyric acid having the absolute stereochemistry of formula (II)
- wherein the hydroxylated carbon at position 3 has (R) stereochemistry, or a pharmaceutically acceptable salt, solvate, hydrate, or composition thereof, and is capable of being retained within the organ or tissue sufficient to emit positrons for detection by positron emission tomography.
3 more elements
A method for monitoring a disorder in a subject comprising:
- administering a radiopharmaceutical to a subject undergoing medical treatment for the disorder;
- imaging an organ or tissue of interest using positron emission tomography;
- and
- comparing the quantity or distribution of the radiopharmaceutical present in the subject with a control quantity or distribution indicative of the effectiveness of the medical treatment;
- wherein the radiopharmaceutical comprises the compound of (S)-[18F]γ-fluoro-β-hydroxybutyric acid having the absolute stereochemistry of formula (I) wherein the hydroxylated carbon at position 3 has (S) stereochemistry, (R)-[18 F]γ-fluoro-β-hydroxybutyric acid having the absolute stereochemistry of formula (II) wherein the hydroxylated carbon at position 3 has (R) stereochemistry, or a pharmaceutically acceptable salt, solvate, hydrate, or composition thereof, and is capable of being retained within the organ or tissue sufficient to emit positrons for detection by positron emission tomography.
2 more elements
Dependencies are inferred from the claim text.